Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1371 clinical trials
Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV (LIMT-2)

The Phase 3 LIMT-2 study will evaluate the safety and efficacy of Peginterferon Lambda treatment for 48 weeks with 24 weeks follow-up compared to no treatment for 12 weeks in patients chronically infected with HDV. The primary analysis will compare the proportion of patients with HDV RNA < LLOQ at …

  • 1 views
  • 19 Jun, 2022
  • 7 locations
YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)

Hepatitis B (+) associated advanced hepatocellular carcinoma. YIV-906 (PHY906, KD018) is an immune system modulator. Clinical and preclinical research suggests that YIV-906 could act to enhance the

  • 2 views
  • 24 Feb, 2022
  • 20 locations
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder (VA-BRAVE)

as well and include: comorbid substance use, both non-fatal and fatal opioid overdose, HIV and Hepatitis C (HCV) testing results and risk behaviors, incarceration, quality of life, psychiatric

  • 263 views
  • 17 Jun, 2022
  • 18 locations
Treatment of Hemochromatosis

blood tests given to all regular volunteer blood donors. These include screening for the HIV and hepatitis viruses and for syphilis. Patients who meet height and weight requirements may be asked

Accepts healthy volunteers
  • 114 views
  • 17 Jun, 2022
  • 1 location
Identification and Validation of Noninvasive Biomarkers of the Diagnosis and Severity of NASH in Type 2 Diabetics (Quid-Nash)

Metabolic diseases of the liver are silent affections whose morbidity is important. About 70% of patients with type 2 diabetes (T2D) are concerned. Of these, 50% develop clinically significant lesions (including non-alcoholic steatohepatitis or NASH) as they are associated with an increased risk of complications; and 15% progress to severe …

Accepts healthy volunteers
  • 0 views
  • 09 Apr, 2022
  • 1 location
Twice Against Thrice-weekly Hemodialysis (TATH)

Hemodialysis is the most worldwide prescribed renal replacement therapy for patients with end-stage renal disease. The frequency of sessions per week remains a debatable issue. In the majority of developed Western and Asian countries, patients on chronic hemodialysis are undergoing three dialysis sessions weekly. In developing countries and some developed …

hypertension
renal replacement therapy
chronic hemodialysis
chronic renal failure
  • 124 views
  • 26 Feb, 2022
  • 1 location
Establishment of a Personalized Pharmaceutical Plan in Renal or Hepatic Transplant Patients (GREPH)

The main objective of the study is to evaluate the impact of the Personalized Pharmaceutical Plan on the therapeutic adherence to immunosuppressive treatments one year after liver or kidney transplantation.

  • 0 views
  • 10 Mar, 2022
  • 4 locations
Hepatitis A Vaccine Dosing Regimens Among Pediatric Rheumatology Patients on Immunosuppressive Therapy

patients on immunosuppressive medications to two different doses of Hepatitis A vaccine. The objectives are (a) to confirm that adolescents, like their adult counterparts, have a reduced immune response to

  • 8 views
  • 24 Feb, 2022
  • 1 location
Therapeutic Hepatitis C Virus Vaccine

GC002 is a Phase I trial to evaluate the safety and the immune responses of a lentiviral based HCV immunotherapy (HCVax) in chronic HCV patients.

  • 5 views
  • 06 Oct, 2021
  • 1 location
Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity

Hepatitis B virus (HBV) leads to life-threatening disease like liver failure and liver cancer. For most, a cure is unattainable as current HBV antiviral therapy (using nucleoside analogues) are

antiviral therapy
antiviral drugs
ribavirin
hepatitis b antigen
tenofovir
  • 0 views
  • 23 Sep, 2021
  • 2 locations